On the recordJuly 27, 2011
If we don't have measurement tools to determine whether a fee system produces a better outcome, then I'm not sure why we would sign off on it as policymakers.
Source
congress.govRichard Burr: “If we don't have measurement tools to determine whether a fee system produces a better outcome, then I'm not sure why we…”
Editor's note · Context
Burr questions the lack of metrics for evaluating FDA fee agreements.
Share
More from Richard Burr
Apr 25, 2022
He was also the author of the Americans With Disabilities Act, helping improve the lives of millions of Americans with disabilities.
Jun 15, 2022
I was surprised and frustrated to hear that these funds were overwhelmingly repurposed from within ASPR, including the stockpile.
May 25, 2022
There is no Member that has defended the FDA more than this one and there is no Member in Congress that has tried to fix areas when they are broken than this one.
Other voices in this conversation
